A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC
Status:
Unknown status
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, multicentre, open-label, randomized, and controlled study, evaluating the
efficacy and safety of combined modularized treatment of treosulfan, pioglitazone and
clarithromycin in patients with with squamous and non- squamous cell lung cancer,
respectively after platin failure.